Lördag 21 December | 18:44:16 Europe / Stockholm

Kalender

Tid*
2026-02-13 N/A Bokslutskommuniké 2025
2025-11-07 08:00 Kvartalsrapport 2025-Q3
2025-08-22 08:00 Kvartalsrapport 2025-Q2
2025-05-23 N/A Årsstämma
2025-05-16 08:00 Kvartalsrapport 2025-Q1
2025-02-14 N/A Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-16 - Kvartalsrapport 2024-Q1
2024-05-13 - X-dag ordinarie utdelning HBC 0.00 NOK
2024-05-10 - Årsstämma
2024-02-09 - Bokslutskommuniké 2023
2024-01-04 - Extra Bolagsstämma 2024
2023-11-10 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-12 - Kvartalsrapport 2023-Q1
2023-05-02 - X-dag ordinarie utdelning HBC 0.00 NOK
2023-04-28 - Årsstämma
2023-02-10 - Bokslutskommuniké 2022
2022-11-11 - Kvartalsrapport 2022-Q3
2022-08-30 - Extra Bolagsstämma 2022
2022-08-26 - Kvartalsrapport 2022-Q2
2022-05-06 - Kvartalsrapport 2022-Q1
2022-05-02 - X-dag ordinarie utdelning HBC 0.00 NOK
2022-04-29 - Årsstämma
2022-02-04 - Bokslutskommuniké 2021
2021-12-03 - Extra Bolagsstämma 2021
2021-11-05 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-21 - Kvartalsrapport 2021-Q1
2021-04-26 - X-dag ordinarie utdelning HBC 0.00 NOK
2021-04-23 - Årsstämma
2021-02-05 - Bokslutskommuniké 2020
2020-11-11 - Extra Bolagsstämma 2020
2020-10-30 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-05-26 - X-dag ordinarie utdelning HBC 0.00 NOK
2020-05-25 - Årsstämma
2020-05-15 - Kvartalsrapport 2020-Q1
2020-02-07 - Bokslutskommuniké 2019
2019-11-01 - Kvartalsrapport 2019-Q3
2019-08-30 - Extra Bolagsstämma 2019
2019-08-30 - Kvartalsrapport 2019-Q2
2019-05-10 - Kvartalsrapport 2019-Q1
2019-04-29 - X-dag ordinarie utdelning HBC 0.00 NOK
2019-04-26 - Årsstämma
2019-02-08 - Bokslutskommuniké 2018
2018-11-02 - Kvartalsrapport 2018-Q3
2018-07-16 - Extra Bolagsstämma 2018
2018-05-09 - Kvartalsrapport 2018-Q1
2018-04-30 - X-dag ordinarie utdelning HBC 0.00 NOK
2018-04-27 - Årsstämma
2018-03-16 - Bokslutskommuniké 2017
2017-11-15 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-25 - Årsstämma
2017-05-12 - Kvartalsrapport 2017-Q1
2017-02-17 - Bokslutskommuniké 2016
2016-11-18 - Kvartalsrapport 2016-Q3
2016-09-20 - Extra Bolagsstämma 2016
2016-08-31 - Kvartalsrapport 2016-Q2
2016-05-20 - Årsstämma
2016-05-20 - Kvartalsrapport 2016-Q1
2016-02-18 - Bokslutskommuniké 2015
2015-11-13 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-05-22 - Årsstämma
2015-04-30 - Kvartalsrapport 2015-Q1
2015-03-27 - Bokslutskommuniké 2014
2014-05-02 - Extra Bolagsstämma 2014
2013-12-27 - Extra Bolagsstämma 2013
2013-06-13 - Kapitalmarknadsdag 2013
2012-10-31 - Kvartalsrapport 2012-Q3
2012-08-22 - Kvartalsrapport 2012-Q2
2012-05-25 - Kvartalsrapport 2012-Q1
2012-02-29 - Bokslutskommuniké 2011

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Hofseth BioCare är ett norskt bolag verksamma inom bioteknik. Bolaget utvecklar diverse högkvalitativt protein- och kalciumpulver, samt laxolja. Genom användandet av patenterad teknik kan bolaget i tidigt stadium utvinna ämnen för produktion. Produkterna levereras i form av kosttillskott och säljs via hälsobutiker. Bolaget grundades 2009 och har sitt huvudkontor i Ålesund.
2024-08-14 13:09:33
Ålesund, Norway, 14 August, 2024 - Hofseth BioCare (HBC), a leader in science-
led marine nutrition, proudly announces compelling new findings from a recent
study on the benefits of its enzymatically liberated salmon oil, OmeGo®, for
COVID-19 recovery.

Published in the International Journal of Molecular Sciences, this pioneering
research demonstrates that OmeGo® has the potential to improve immune responses
and reduce inflammation in individuals with mild to moderate COVID-19 infection,
caused by the SARS-CoV-2 virus.

The study found that subjects taking OmeGo® had significantly lower levels of
pro-inflammatory cytokines, which is vital for reducing the acute inflammatory
response linked to the complications of COVID-19. Additionally, OmeGo®
supplementation led to better interferon-related gene expression, essential for
effective viral clearance and maintaining a balanced immune response.
Participants also showed improved lung barrier function and enhanced immune
memory, indicating a strong and lasting immune defence.

The research sheds light on the potential role of whole salmon oil in managing
long COVID, a condition affecting an estimated 65 million people globally, and
presents significant opportunities for nutraceutical companies seeking
scientifically-backed, natural, and well-tolerated solutions to enhance immune
health.

Dr. Crawford Currie, lead author and Head of Medical R&D at HBC, comments: "The
Covid-19 pandemic cast immune health under the spotlight and since then,
consumers worldwide have been exploring solutions to proactively boost their
viral defences. The broad-spectrum benefits of our enzymatically liberated
salmon oil stand as a beacon of hope, with this latest study demonstrating its
power to modulate the immune response, aid recovery and reduce the risk of
severe outcomes. OmeGo® encapsulates the essence of whole fish, offering
profound health benefits that extend beyond nutrition to help fortify our immune
systems and support recovery from viral infections."

OmeGo®, derived from Norwegian Atlantic salmon, mirrors the lipid profile of
whole salmon and provides unique anti-inflammatory and anti-allergic benefits
distinct from omega-3 alone. When combined with previous studies, this latest
discovery underlines OmeGo®'s position as a one-of-a-kind salmon oil - offering
lung, cardiovascular, joint, and immune function support.

It also builds on the bank of evidence that underutilised salmon off-cuts are a
sustainable, zero-waste resource for optimal nutritional performance.?HBC is now
in the process of conducting another study to assess the impact of OmeGo® on
respiratory symptoms, sleep quality and inflammation in urban-dwelling subjects
affected by pollution, with results expected before the end of 2024.

Find the full scientific study here (https://www.mdpi.com/1422-
0067/25/13/6917) or for more information contact the Hofseth BioCare team:
Hofseth BioCare | Research and development (https://hofsethbiocare.com/research-
and-technology).

About HBC:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. For OmeGo®, clinical trial work with our
salmon oil is ongoing to improve lung health in allergic asthma and urban
populations with exposure to raised pollution levels. A study in mild COVID has
completed successfully demonstrating important immune health benefits for faster
recovery. For CalGo®, preclinical and clinical trial work is delineating the
joint health benefits of the natural, undenatured type II collagen contained in
it. ProGo® provides both metabolic and gastrointestinal (GI) health benefits.
The former includes GLP1 activity and hence consistent weight loss with improved
energy levels from improved iron metabolism. The peptides also support muscle
health providing a triad of benefits important for healthy ageing and active
lifestyles. In terms of GI health, a special formula of soluble protein
hydrolysate (SPH / ProGo®) is being developed as a Medical Food to help treat
Inflammatory Bowel Disease, and for Iron Deficiency Anemia. Research is ongoing
to identify the individual elements within its ingredients that modulate
inflammation and the immune response with pre-clinical studies ongoing in
multiple clinics and University research labs.

The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of the lipids, proteins and calcium
from fresh salmon off-cuts. HBC's headquarters are in Ålesund, Norway with
branches in Oslo, London, Zürich, New Jersey and Palo Alto. HBC is listed on
Oslo Børs with ticker "HBC".

For further information on HBC, please contact:
Dr. Crawford Currie, Head of Medical R&D
cc@hofsethbiocare.com

For press information or to arrange an interview, please contact:
Sara Houghton, BDB
hofsethbiocare@bdb.co.uk